ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Rochester, MN, USA:

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Biological: Best Available Therapy (BAT)
Procedure: Autologous Hematopoietic Stem Cell Transplantation

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Rochester, Minnesota, United States and 18 other locations

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Drug: Siponimod
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Rochester, Minnesota, United States and 72 other locations

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-p...

Active, not recruiting
Amyotrophic Lateral Sclerosis
ALS
Drug: Placebo
Drug: ABBV-CLS-7262

Phase 1

Calico Life Sciences

Rochester, Minnesota, United States and 13 other locations

(PK) of RO7303509 treatment in participants with systemic sclerosis (SSc) during a multiple-ascending-dose (MAD) portion of the tri...

Enrolling
Systemic Sclerosis
Drug: Placebo
Drug: RO7303509

Phase 1

Genentech
Genentech

Rochester, Minnesota, United States and 41 other locations

The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to ina...

Enrolling
Multiple Sclerosis
Spinal Cord Injuries (Complete and Incomplete)
Device: SCONE
SpineX

Rochester, Minnesota, United States and 11 other locations

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple...

Enrolling
Primary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo

Phase 3

Sanofi
Sanofi

Rochester, Minnesota, United States and 291 other locations

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMSSecondary Objective:To evalu...

Active, not recruiting
Secondary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo to match Tolebrutinib

Phase 3

Sanofi
Sanofi

Rochester, Minnesota, United States and 300 other locations

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with development...

Enrolling
Developmental and Epileptic Encephalopathy
Lennox-Gastaut Syndrome
Drug: LP352

Phase 2

Longboard Pharmaceuticals

Rochester, Minnesota, United States and 27 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems